Posted: 2 September 2025
Nutromics, a diagnostics innovator based in Melbourne, announced it had raised A$7.5 million in a new acceleration round. The financing was led by a specialist Australian life sciences investor and lifts the company’s cumulative funding to A$60 million.
In recent years, Nutromics has accelerated progress on its proprietary “lab-on-a-patch®” device, designed to provide continuous, real-time molecular insights that could reshape both diagnostics and personalised medicine.
“Our world first clinical study, completed in 2024, showed successful results,” Nutromics CEO and co-founder Peter Vranes said. “We’re now conducting ICU trials, a global first for this class of wearable diagnostics. We’ve significantly de-risked our first product, and this latest raise reflects growing investor confidence in our execution.”
The company’s platform combines DNA-based biosensors with microneedle technology and advanced data analytics, enabling real-time drug monitoring. Nutromics’ initial commercial focus is vancomycin, a vital but complex antibiotic, for which the company is targeting FDA approval in 2028. Future plans include expanding into sepsis, cardiology, triage, and other clinical areas.
Alongside its own studies, Nutromics is collaborating with pharmaceutical partners, providing research-use-only wearable devices to support clinical trial monitoring. This marks the company’s first pathway to commercial revenue.
To enable scaling and commercial rollout, Nutromics plans to establish a state-of-the-art manufacturing hub, ideally located in Australia. The facility is projected to create over 100 specialised jobs and generate up to US$1.5 billion in annual exports, contingent on investor and government support.
Commenting on Nutromics’ growth, Stuart Dignam, CEO of MTPConnect, said: “Australia can’t afford to treat advanced manufacturing as secondary to discovery. Nutromics is a promising MedTech company emerging from Australia’s R&D pipeline with the potential to scale into global markets from here. We have lost too many companies that were built on Australian science but scaled offshore. Backing this facility now is an opportunity where public and industry co-investment can unlock significant economic, clinical, and strategic value and help move our life sciences sector from innovation to industry.”
Nutromics is guided by experienced leadership, including Dr Chris Roberts AO, former CEO of Cochlear and current Non-Executive Director of ResMed, who chairs its board. The company was also named among nine participants in the Victorian Government’s inaugural 30X30 program, aimed at fast-tracking startups toward unicorn status by 2030.
“Australia is uniquely positioned to lead in advanced medical device development and export,” said Hitesh Mehta, COO and co-founder. “We attract elite talent, our clinical trial ecosystem is unrivalled, and several life-changing technologies have been born here. At Nutromics, we’ve benefited from this foundation as a startup. Our next focus is scaling, and our advanced manufacturing facility will help create jobs, drive innovation, and build valuable IP. This is the natural next stage in our growth.”
For more information click here.
